{"id":"e58c37c43eba","type":"article","url":"https://hartvaat.nl/2025/08/14/plaque-remodeling-als-surrogaat-voor-ernstige-cardiale-events/","title":"Plaque-remodeling als surrogaat voor ernstige cardiale events","title_en":"Plaque remodelling as a surrogate for major adverse cardiac events","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["atherosclerose","plaquekarakterisatie","secundaire-preventie"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01379-6/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01379-6/fulltext","authors":["G.B. John Mancini"],"significance":4,"published":"2025-08-14","source_date":"2025-08-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This commentary discusses plaque remodelling as a surrogate endpoint for major adverse cardiac events in the context of intensive lipid-lowering therapy. The use of imaging-based plaque assessment as a trial endpoint has evolved since the classic FATS trial.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De ontwikkeling van veilige en effectieve lipidenverlagende middelen was een mijlpaal in de cardiovasculaire geneeskunde. Dit commentaar bespreekt plaque-remodeling als surrogaatmarker voor ernstige cardiovasculaire events.","abstract_original":"The advent of safe and effective lipid lowering agents that could be tolerated over the relatively long term to sustain intensive reduction of low density lipoprotein-cholesterol (LDL-C) was a major milestone in cardiovascular medicine. Angiographic trials such as the classic Familial Atherosclerosis Treatment Study (FATS) trial demonstrated the ability of aggressive and sustained lipid lowering therapy to profoundly slow the rate of progression and even induce regression of established coronary atherosclerosis [1]."}